Research programme: small molecule therapeutics - GT Biopharma

Drug Profile

Research programme: small molecule therapeutics - GT Biopharma

Alternative Names: OXS 4135; OXS 4235; p62-zz inhibitors - GT Biopharma

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ID4 Pharma
  • Developer GT Biopharma; ID4 Pharma
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; SQSTM1 protein inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Osteolysis

Most Recent Events

  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 31 Mar 2017 ID4 Pharma has patents pending for p62-zz inhibitors in China
  • 04 Aug 2015 Oxis Biotech executes amended option agreement with the University of Pittsburgh
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top